| Co-hosted with the Foundation for Medical Innovation (FMI)… Program runs from June 9 to July 9
| Curriculum focuses on real-world investment strategies and growth case studies for biotech startups
Global biopharmaceutical accelerator JNPMEDI Partners (CEO KwunHo Jeong) will launch a hands-on training program titled ‘FMI X JNPMEDI Partners Biotech Venture School’ in collaboration with the Foundation for Medical Innovation (Chairman SeungKyu Lee), targeting aspiring entrepreneurs and early-stage startups in the bio-healthcare industry. The one-month program will run from June 9 to July 9. Co-developed with the Foundation for Medical Innovation, the program is currently accepting applications until Wednesday, May 14.
This venture school was designed to systematically convey investment mechanisms and fundraising strategies often overlooked in the biotech startup ecosystem. In particular, the program will allow founders to reframe their business strategies and refine execution plans from an investor’s perspective, leveraging insights from active VC investors and firsthand experiences of successful startup founders.
The curriculum consists of four stages: ▲Stage 1 – Understanding VC and investment structures, ▲Stage 2 – Key trends and strategies in the pharmaceutical and biotech industries, ▲Stage 3 – Investment case analysis led by VC professionals, ▲Stage 4 – Practical insights focused on biotech startup growth stories. The sessions will be conducted both online and offline, with the first and final sessions held in-person at Yoon Deok-byeong Hall of Seoul National University Hospital and JNPMEDI headquarters, respectively.
The program is open to prospective entrepreneurs or early-stage company members in the pharmaceutical, biotech, and healthcare sectors. Up to 20 companies will be selected, and the participation fee is KRW 700,000 per company. Notably, the top-performing graduate will have an opportunity to secure investment of up to KRW 100 million.
Applications can be submitted online through the official websites of JNPMEDI Partners or the Foundation for Medical Innovation. After submitting an application by May 14, the selection process will proceed in the following order: document screening (May 19), in-person interviews (May 26–28), and final registration (May 30–June 6).
JungEun Kim, Senior Investment Manager at JNPMEDI Partners, stated, “This venture school is a practical program that interprets the startup growth process—beyond technology—through the eyes of investors. It will offer a concrete execution framework for founders seeking to clarify their business fundamentals and funding strategies.”
KiYoung Kim, CIO of the Foundation for Medical Innovation, commented, “One of the greatest challenges facing biotech startups is the lack of understanding of VC mechanisms and the resulting misalignment in perspectives with investors. We hope this program becomes a special opportunity for founders to understand the core of the investment ecosystem and major trends, enabling them to maximize their company’s value.”
Meanwhile, JNPMEDI Partners has been actively engaged in early-stage investment and co-business development with startups in biotech and digital health. Starting with this venture school, the firm plans to expand strategic partnerships with outstanding founders and establish regular educational programs.
📌 Apply Now : Click here
| Co-hosted with the Foundation for Medical Innovation (FMI)… Program runs from June 9 to July 9
| Curriculum focuses on real-world investment strategies and growth case studies for biotech startups
Global biopharmaceutical accelerator JNPMEDI Partners (CEO KwunHo Jeong) will launch a hands-on training program titled ‘FMI X JNPMEDI Partners Biotech Venture School’ in collaboration with the Foundation for Medical Innovation (Chairman SeungKyu Lee), targeting aspiring entrepreneurs and early-stage startups in the bio-healthcare industry. The one-month program will run from June 9 to July 9. Co-developed with the Foundation for Medical Innovation, the program is currently accepting applications until Wednesday, May 14.
This venture school was designed to systematically convey investment mechanisms and fundraising strategies often overlooked in the biotech startup ecosystem. In particular, the program will allow founders to reframe their business strategies and refine execution plans from an investor’s perspective, leveraging insights from active VC investors and firsthand experiences of successful startup founders.
The curriculum consists of four stages: ▲Stage 1 – Understanding VC and investment structures, ▲Stage 2 – Key trends and strategies in the pharmaceutical and biotech industries, ▲Stage 3 – Investment case analysis led by VC professionals, ▲Stage 4 – Practical insights focused on biotech startup growth stories. The sessions will be conducted both online and offline, with the first and final sessions held in-person at Yoon Deok-byeong Hall of Seoul National University Hospital and JNPMEDI headquarters, respectively.
The program is open to prospective entrepreneurs or early-stage company members in the pharmaceutical, biotech, and healthcare sectors. Up to 20 companies will be selected, and the participation fee is KRW 700,000 per company. Notably, the top-performing graduate will have an opportunity to secure investment of up to KRW 100 million.
Applications can be submitted online through the official websites of JNPMEDI Partners or the Foundation for Medical Innovation. After submitting an application by May 14, the selection process will proceed in the following order: document screening (May 19), in-person interviews (May 26–28), and final registration (May 30–June 6).
JungEun Kim, Senior Investment Manager at JNPMEDI Partners, stated, “This venture school is a practical program that interprets the startup growth process—beyond technology—through the eyes of investors. It will offer a concrete execution framework for founders seeking to clarify their business fundamentals and funding strategies.”
KiYoung Kim, CIO of the Foundation for Medical Innovation, commented, “One of the greatest challenges facing biotech startups is the lack of understanding of VC mechanisms and the resulting misalignment in perspectives with investors. We hope this program becomes a special opportunity for founders to understand the core of the investment ecosystem and major trends, enabling them to maximize their company’s value.”
Meanwhile, JNPMEDI Partners has been actively engaged in early-stage investment and co-business development with startups in biotech and digital health. Starting with this venture school, the firm plans to expand strategic partnerships with outstanding founders and establish regular educational programs.
📌 Apply Now : Click here